-
Mashup Score: 2Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy - 1 month(s) ago
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
China’s National Medical Products Administration has approved #tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy. https://t.co/Mr77xQiSEU